Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
24.29
+0.09 (0.37%)
At close: Mar 28, 2025, 4:00 PM
25.16
+0.87 (3.58%)
After-hours: Mar 28, 2025, 6:25 PM EDT
Simulations Plus Revenue
Simulations Plus had revenue of $18.92M in the quarter ending November 30, 2024, with 30.51% growth. This brings the company's revenue in the last twelve months to $74.44M, up 19.84% year-over-year. In the fiscal year ending August 31, 2024, Simulations Plus had annual revenue of $70.01M with 17.52% growth.
Revenue (ttm)
$74.44M
Revenue Growth
+19.84%
P/S Ratio
6.53
Revenue / Employee
$301,364
Employees
247
Market Cap
488.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
Aug 31, 2019 | Pro | Pro | Pro |
Aug 31, 2018 | Pro | Pro | Pro |
Aug 31, 2017 | Pro | Pro | Pro |
Aug 31, 2016 | Pro | Pro | Pro |
Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SLP News
- 4 days ago - Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga
- 10 days ago - Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date - Business Wire
- 20 days ago - Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum - Business Wire
- 7 weeks ago - Simulations Plus to Participate in Upcoming Healthcare Investor Conferences - Business Wire
- 2 months ago - Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements - Business Wire
- 2 months ago - Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024 - Business Wire
- 2 months ago - Simulations Plus Supported Development of Every FDA-Approved Drug in 2024 - Business Wire
- 2 months ago - Simulations Plus, Inc. (SLP) Q1 2025 Earnings Call Transcript - Seeking Alpha